ArticleOpen veterinary journal2025
Combined extracts of
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigation of cisplatin-induced acute kidney injury using LC-HRMS and network pharmacology approaches in mixedOpen veterinary journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cisplatin (CIS) is a highly effective chemotherapeutic drug. However, it is associated with various side effects, including kidney damage, due to its nephrotoxic properties. Aim: This study aimed to evaluate the renoprotective potential of the combined extract of Methods: Twenty-five rats were divided into normal control groups (NS), CIS control groups, and three treatment groups that received doses of the combined extract at 100, 200, and 400 mg/kg (CUR100, CUR200, and CUR400), respectively, on day 1-20. All groups, except the NS group (receiving normal saline i.p.), received intraperitoneal CIS (1 mg/kg) on days 7 and 14 of the 20-day extract treatment. Results: Compared with the rats in the CIS group, rats given the combined extract had a considerable gain in body weight and decreased TNF-α, KIM-1, and caspase-3 expression levels. Histopathological examination revealed that the extract group experienced less kidney damage than the CIS group. The combined extract, administered at 200 mg/kg, exerted the most apparent protective effect, decreasing renal TNF-α, KIM-1, and caspase 3. Conclusion: The combined extract of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.